Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2022Cerebrovascular DiseasesOpen Access

Association of Intravenous Tirofiban with Functional Outcomes in Acute Ischemic Stroke Patients with Acute Basilar Artery Occlusion Receiving Endovascular Thrombectomy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To evaluate whether intravenous tirofiban improves functional outcomes without increasing the risk of intracranial hemorrhage in patients with acute basilar artery occlusion undergoing endovascular thrombectomy.

Does intravenous tirofiban improve functional outcomes in patients with acute basilar artery occlusion stroke receiving endovascular thrombectomy?

Population

645 acute basilar artery occlusion stroke patients receiving endovascular thrombectomy

Comparison

Intravenous tirofiban vs no-tirofiban

Design

Nationwide prospective registry-based cohort study

Follow-up

90-day

Authors

QCQiong ChenMinistry of Education of the People's Republic of ChinaRMRenliang MengAffiliated Hospital of Southwest Medical UniversityDWDeping WuZhongda Hospital Southeast University

Discussion

Loading...

Member takes

Implication

Supports tirofiban adjunct in basilar thrombectomy; hypothesis-generating pending randomized confirmation.

Structured PICO

Does intravenous tirofiban improve functional outcomes in patients with acute basilar artery occlusion stroke receiving endovascular thrombectomy?

P
Population
645 patients with acute ischemic stroke secondary to basilar artery occlusion (BAO) receiving endovascular thrombectomy, derived from a nationwide prospective registry
I
Intervention
Intravenous tirofiban
C
Comparator
No intravenous tirofiban
O
Outcome
90-day severity of disability as assessed by the modified Rankin scale scorehard clinical

Intravenous tirofiban during endovascular thrombectomy for acute basilar artery occlusion is associated with improved functional outcomes, reduced mortality, and a decreased risk of intracranial hemorrhage.

Cite This Study

Chen et al. (2022) studied this question.

synapsesocial.com/papers/6a81e1ed5bcfff97abe03f8bhttps://doi.org/10.1159/000527483
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban2001 · 2,117 citations
  2. 2Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions2000 · 76 citations
  3. 3Endovascular treatment with versus without tirofiban for stroke patients with large vessel occlusion: The multicenter, randomized, placebo-controlled, double-blind RESCUE BT study protocol2022 · 14 citations
  4. 4Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke2019 · 72 citations
  5. 5Endovascular Stroke Therapy2013 · 191 citations